These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 16419269

  • 1. Preclinical assessment of the proinflammatory potential of microbicide candidates.
    Doncel GF, Chandra N, Fichorova RN.
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S174-80. PubMed ID: 16419269
    [Abstract] [Full Text] [Related]

  • 2. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
    Catalone BJ, Kish-Catalone TM, Budgeon LR, Neely EB, Ferguson M, Krebs FC, Howett MK, Labib M, Rando R, Wigdahl B.
    Antimicrob Agents Chemother; 2004 May; 48(5):1837-47. PubMed ID: 15105142
    [Abstract] [Full Text] [Related]

  • 3. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives.
    Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF.
    Biol Reprod; 2004 Sep; 71(3):761-9. PubMed ID: 15128598
    [Abstract] [Full Text] [Related]

  • 4. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat.
    D'Cruz OJ, Uckun FM.
    Toxicol Pathol; 2007 Dec; 35(7):910-27. PubMed ID: 18098038
    [Abstract] [Full Text] [Related]

  • 5. Guiding the vaginal microbicide trials with biomarkers of inflammation.
    Fichorova RN.
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3(Suppl 3):S184-93. PubMed ID: 16419271
    [Abstract] [Full Text] [Related]

  • 6. Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission.
    Yang J, Li L, Jin H, Tan S, Qiu J, Yang L, Ding Y, Jiang ZH, Jiang S, Liu S.
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1498-508. PubMed ID: 22867271
    [Abstract] [Full Text] [Related]

  • 7. Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety.
    Lozenski K, Ownbey R, Wigdahl B, Kish-Catalone T, Krebs FC.
    BMC Pharmacol Toxicol; 2012 Oct 01; 13():9. PubMed ID: 23025553
    [Abstract] [Full Text] [Related]

  • 8. L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide.
    Zhong M, He B, Yang J, Bao R, Zhang Y, Zhou D, Chen Y, Li L, Han C, Yang Y, Sun Y, Cao Y, Li Y, Shi W, Jiang S, Zhang X, Yan H.
    Antimicrob Agents Chemother; 2012 Jun 01; 56(6):3121-32. PubMed ID: 22391529
    [Abstract] [Full Text] [Related]

  • 9. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety.
    Cummins JE, Doncel GF.
    Sex Transm Dis; 2009 Mar 01; 36(3 Suppl):S84-91. PubMed ID: 19218890
    [Abstract] [Full Text] [Related]

  • 10. Increased COX-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection.
    Zalenskaya IA, Cerocchi OG, Joseph T, Donaghay MA, Schriver SD, Doncel GF.
    Am J Reprod Immunol; 2011 Jun 01; 65(6):569-77. PubMed ID: 21241401
    [Abstract] [Full Text] [Related]

  • 11. A quantitative multiplex nuclease protection assay reveals immunotoxicity gene expression profiles in the rabbit model for vaginal drug safety evaluation.
    Fichorova RN, Mendonca K, Yamamoto HS, Murray R, Chandra N, Doncel GF.
    Toxicol Appl Pharmacol; 2015 Jun 15; 285(3):198-206. PubMed ID: 25818602
    [Abstract] [Full Text] [Related]

  • 12. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.
    Fichorova RN, Tucker LD, Anderson DJ.
    J Infect Dis; 2001 Aug 15; 184(4):418-28. PubMed ID: 11471099
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of immunological markers of ovine vaginal irritation: Implications for preclinical assessment of non-vaccine HIV preventive agents.
    Milligan GN, Vargas G, Vincent KL, Zhu Y, Bourne N, Motamedi M.
    J Reprod Immunol; 2017 Nov 15; 124():38-43. PubMed ID: 29054075
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation.
    Fichorova RN, Zhou F, Ratnam V, Atanassova V, Jiang S, Strick N, Neurath AR.
    Antimicrob Agents Chemother; 2005 Jan 15; 49(1):323-35. PubMed ID: 15616312
    [Abstract] [Full Text] [Related]

  • 16. WHI-05, a novel bromo-methoxy substituted phenyl phosphate derivative of zidovudine, is a dual-action spermicide with potent anti-HIV activity.
    D'Cruz OJ, Zhu Z, Yiv SH, Chen CL, Waurzyniak B, Uckun FM.
    Contraception; 1999 May 15; 59(5):319-31. PubMed ID: 10494486
    [Abstract] [Full Text] [Related]

  • 17. The role of biopsy in vaginal microbicide development.
    Low-Beer N.
    J Acquir Immune Defic Syndr; 2004 Oct 15; 37 Suppl 3():S181-3. PubMed ID: 16419270
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Establishing a Th17 based mouse model for preclinical assessment of the toxicity of candidate microbicides.
    Li LZ, Yang Y, Yuan SH, Wan YM, Qiu C, Feng YL, Xu JQ, Zhang XY.
    Chin Med J (Engl); 2010 Dec 15; 123(23):3381-8. PubMed ID: 22166518
    [Abstract] [Full Text] [Related]

  • 20. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.
    Trifonova RT, Pasicznyk JM, Fichorova RN.
    Antimicrob Agents Chemother; 2006 Dec 15; 50(12):4005-10. PubMed ID: 17030562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.